Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Rhea-AI Summary

Immunovant (Nasdaq: IMVT) has announced an investor webcast scheduled for September 9, 2024, at 8:00 a.m. ET to provide updates on its Graves' Disease (GD) program. The presentation will cover:

• New epidemiologic data on the potential addressable market
• Additional results from the Phase 2 study of batoclimab
• An overview of the IMVT-1402 development program in GD

Investors can register for the event through a provided link, and a live webcast will be available on Immunovant's website. A replay of the event and presentation will be accessible immediately after the webcast concludes.

News Market Reaction – IMVT

+9.55%

1 alert

+9.55% News Effect

On the day this news was published, IMVT gained 9.55%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Investor webcast on Monday, September 9th at 8:00 a.m. ET

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9^th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program.

The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD.

Webcast Details

The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Investor Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com

Source: Immunovant Inc.

FAQ

When is Immunovant's investor webcast for the Graves' Disease program update?

Immunovant's investor webcast for the Graves' Disease program update is scheduled for Monday, September 9, 2024, at 8:00 a.m. ET.

What topics will be covered in Immunovant's Graves' Disease program update?

The update will cover new epidemiologic data on the potential addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in Graves' Disease.

How can investors access Immunovant's Graves' Disease program update webcast?

Investors can register for the webcast through a provided link, and a live webcast will be available under the News & Events section of Immunovant's website. A replay will be available immediately after the event.

What is Immunovant's stock symbol?

Immunovant's stock symbol is IMVT, and it is listed on the Nasdaq stock exchange.